BTIG Research lowered shares of ABIOMED, Inc. (NASDAQ:ABMD) from a buy rating to a neutral rating in a research note published on Monday, Marketbeat.com reports.

Other analysts also recently issued reports about the company. Piper Jaffray Companies set a $145.00 price objective on ABIOMED in a report on Tuesday, July 4th. BidaskClub upgraded ABIOMED from a hold rating to a buy rating in a report on Thursday, August 10th. Jefferies Group LLC restated a buy rating and set a $175.00 price objective on shares of ABIOMED in a report on Tuesday, August 29th. SunTrust Banks, Inc. initiated coverage on ABIOMED in a report on Friday, September 29th. They set a buy rating and a $195.00 price objective for the company. Finally, Morgan Stanley restated an equal weight rating and set a $140.00 price objective (up from $135.00) on shares of ABIOMED in a report on Monday, July 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. ABIOMED currently has an average rating of Buy and a consensus target price of $173.25.

ABIOMED (NASDAQ ABMD) opened at 172.95 on Monday. The company has a 50-day moving average price of $163.04 and a 200 day moving average price of $145.57. The stock has a market capitalization of $7.63 billion, a price-to-earnings ratio of 101.14 and a beta of 0.27. ABIOMED has a 12 month low of $95.14 and a 12 month high of $175.71.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. The business had revenue of $132.47 million during the quarter, compared to the consensus estimate of $130.83 million. ABIOMED had a return on equity of 13.03% and a net margin of 16.13%. The business’s revenue for the quarter was up 28.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.29 EPS. Equities analysts predict that ABIOMED will post $2.24 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/10/19/abiomed-inc-abmd-cut-to-neutral-at-btig-research.html.

In related news, Director Paul Thomas sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $154.71, for a total transaction of $1,547,100.00. Following the completion of the sale, the director now directly owns 12,172 shares of the company’s stock, valued at approximately $1,883,130.12. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Andrew J. Greenfield sold 11,282 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $169.32, for a total transaction of $1,910,268.24. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,782 shares of company stock valued at $9,513,610. 7.00% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. Huntington National Bank purchased a new stake in ABIOMED during the 2nd quarter worth $100,000. Seven Eight Capital LP purchased a new stake in ABIOMED during the 2nd quarter worth $100,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in ABIOMED by 15.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,511 shares of the medical equipment provider’s stock worth $217,000 after purchasing an additional 197 shares during the period. Private Bank & Trust Co. purchased a new stake in ABIOMED during the 2nd quarter worth $226,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in ABIOMED during the 1st quarter worth $244,000. 89.37% of the stock is owned by hedge funds and other institutional investors.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.